Back

Comparative effectiveness of finerenone versus spironolactone in patients hospitalized with heart failure: a prospective cohort study

31 August 2026 (12:10 - 12:20)
Organised by: Logo
Congress Presentation Part of: Transforming heart failure with next-generation therapies and mechanisms Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Miss Ruo'nan Xiao

Chongqing (China)

4 More presentations in this session

Presentation thumbnail
Phase Ib study of intravenous HRS-9057, an arginine vasopressin V2 receptor antagonist, versus oral tolvaptan in congestive heart failure with volume overload despite prior diuretic therapy
Professor W. Ou (CN)
Abstract
Presentation thumbnail
Optimizing mineralocorticoid receptor antagonist therapy with sodium zirconium cyclosilicate in heart failure
Doctor C. Basic (Gothenburg, SE)
Abstract
Presentation thumbnail
The effect of quality of life on all cause mortality in tafamidis treated vs. placebo ATTR-CM patients: post hoc analyses from the ATTR-ACT study
Doctor F. Cappelli (Florence, IT)
Abstract
Presentation thumbnail
Pyruvate metabolism enzyme Dlat induces mitochondria protein hyperacetylation to limit fatty acid oxidation in the HFpEF heart
Doctor Y. Wang (CN)
Abstract

Access the full session

Session thumbnail
Transforming heart failure with next-generation therapies and mechanisms

The Event

Event poster

ESC Congress 2026

31 August 2026 12:10 CET
You may be interested in
thumbnail
Congress Presentation
Eplerenone versus spironolactone and outcomes in patients with heart failure: a nationwide cohort study
21 May 2022
thumbnail
Congress Presentation
FINARM study versus FINE-HEART pooled analysis: comparative analysis of patients with heart failure and diabetic kidney disease
18 May 2025
thumbnail
Congress Presentation
Effects of metolazone on congestion and diuretic efficiency in patients hospitalized for advanced heart failure
29 June 2021
thumbnail
Congress Presentation
The non-steroidal mineralocorticoid receptor antagonist finerenone prevents structural cardiac remodeling
3 September 2019

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources